HC Wainwright initiates Gyre with a Buy rating and $18 price target. Hydronidone is projected to reach $6 billion in annual U.S. sales by 2033. See the trading strategy with a perfect track record in ...

To be considered for this list, a deck needs to tick a few boxes. For one, it needs to be available, and not just on the secondary market. While some of these are getting harder to find, you can still ...

Amazon dieback”, as this grim scenario is known, is just one example of what climate scientists refer to as a tipping point: ...

Francisco was a tropical depression in the East China Sea Friday evening Taiwan time, the Joint Typhoon Warning Center said in its latest advisory. The storm formed in the Western Pacific Ocean at ...

Marine plastic litter tends to grab headlines, with images of suffocating seabirds or bottles washing up along coastlines. Increasingly, researchers have been finding tiny microplastic fragments ...

Gyre Therapeutics is headquartered in San Diego, CA. The company is focused on development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across ...